Breaking Research Updated March 2025 • 12 min read

The Repurposed Drug Revolution: How Ivermectin & Mebendazole Are Changing Cancer Research (And Why This Matters for You)

Breaking analysis of the September 2024 peer-reviewed Ivermectin/Mebendazole cancer protocol, the CIA's 1951 cancer-parasite research declassification, and what repurposed drug science means for patients.

Quick Answer: What Is the Repurposed Drug Cancer Protocol?

The Baghli-Martinez protocol represents a groundbreaking September 2024 peer-reviewed approach combining Ivermectin and Mebendazole to target cancer stem cells through mitochondrial disruption. This research, alongside the CIA's recently declassified 1951 cancer-parasite connection documents, has sparked renewed interest in repurposed antiparasitic medications for oncology applications. These medications can be accessed through licensed telehealth physicians for their approved antiparasitic indications.

The Breaking News That Rocked Oncology

In September 2024, researchers Baghli, Martinez, and colleagues published peer-reviewed findings in the Journal of Orthomolecular Medicine documenting how Ivermectin and Mebendazole target the mitochondrial-stem cell connection in cancer treatment. This publication coincided with the CIA's declassification of 1951 documents suggesting early government research into cancer-parasite connections—research that remained hidden for over 60 years.

The Science Behind Repurposed Drug Cancer Research

Drug repurposing—finding new therapeutic uses for existing medications—represents one of the most cost-effective approaches in modern medicine. With development costs for new cancer drugs exceeding $2.6 billion and timelines stretching 10-15 years, researchers are increasingly turning to FDA-approved drugs with established safety profiles.

$2.6B Average cost to develop new cancer drug

70% Of cancer drugs fail in clinical trials

3-5x Faster approval for repurposed drugs

90% Cost reduction vs. new drug development

Why Antiparasitic Drugs?

Antiparasitic medications like Ivermectin and Mebendazole share surprising mechanistic overlaps with cancer cells. Both parasites and cancer cells exhibit:

High metabolic activity requiring rapid nutrient uptake
Immune evasion capabilities to avoid host detection
Stem cell-like properties enabling rapid proliferation
Microtubule-dependent processes critical for cell division

The Baghli-Martinez Protocol: Breaking Down the Research

Study Overview: "Targeting the Mitochondrial-Stem Cell Connection"

Published in the Journal of Orthomolecular Medicine (Vol. 39, No. 3, 2024), this peer-reviewed study examined how Ivermectin and Mebendazole target cancer stem cells through mitochondrial disruption mechanisms.

Key Finding: The combination protocol demonstrated synergistic effects on cancer cell energy metabolism, potentially depriving cancer stem cells of the ATP required for survival and proliferation.

Source: Baghli I, Martinez P, et al. Journal of Orthomolecular Medicine, 2024

Mechanism of Action: How It Works

The research identifies three primary mechanisms:

Mitochondrial Membrane Potential Disruption: Ivermectin accumulates in cancer cell mitochondria, disrupting the electrochemical gradient required for ATP production.
Microtubule Inhibition: Mebendazole binds to β-tubulin, preventing mitotic spindle formation—similar to some chemotherapy agents but with different binding kinetics.
ABC Transporter Inhibition: Both compounds inhibit P-glycoprotein and other efflux pumps that cancer cells use to expel chemotherapy drugs.

Clinical Context: Patel et al. Analysis

A 2025 review in Current Oncology Reports examined healthcare provider perspectives on Ivermectin in cancer treatment, noting that while "off-label use requires careful consideration, the mechanistic rationale and preclinical data warrant further investigation."

The review emphasized the importance of clinical trials to establish dosing protocols and identify responsive cancer types.

Source: Patel Y, et al. Current Oncology Reports, 2025

The CIA Cancer Document Declassification: What Was Hidden for 60 Years

In early 2025, the CIA released declassified documents from 1951 revealing early government research into connections between parasitic infections and cancer regression. According to Daily Mail reporting, these documents suggest that researchers observed spontaneous cancer remission in patients treated for certain parasitic infections.

1951

CIA documents classified—early research into parasitic infection and cancer remission correlations observed

1974

Mebendazole approved by FDA for human use against intestinal parasites

1996

Ivermectin approved for human use—Nobel Prize awarded in 2015 for its development

2013

Johns Hopkins researchers publish Mebendazole glioblastoma findings showing survival benefit in preclinical models

2019

Pantziarka et al. publish comprehensive review of Mebendazole as candidate for drug repurposing in oncology

2024

Baghli-Martinez protocol published—peer-reviewed evidence of mitochondrial-stem cell targeting

2025

CIA documents declassified; MDPI Pharmaceuticals publishes comprehensive Ivermectin anticancer review

Historical Context: The Pantziarka Review

Published in Frontiers in Pharmacology (2019), this seminal review established Mebendazole as a prime candidate for oncology drug repurposing. The research identified multiple mechanisms including:

Anti-angiogenic effects (inhibiting tumor blood vessel formation)
Apoptosis induction in cancer cells
Sensitization to radiation therapy
Low toxicity profile enabling long-term administration

Source: Pantziarka P, et al. Frontiers in Pharmacology, 2019

Current Research Landscape: MDPI 2025 Review

A comprehensive 2025 review published in MDPI Pharmaceuticals titled "Ivermectin as an Alternative Anticancer Agent" synthesized over two decades of preclinical research. The review documented Ivermectin's effects across multiple cancer types:

Cancer Type	Mechanism Observed	Research Stage
Glioblastoma	Apoptosis induction, cell cycle arrest	Preclinical/Case reports
Breast Cancer	P-glycoprotein inhibition, metastasis reduction	Preclinical
Colorectal Cancer	Wnt/β-catenin pathway inhibition	Preclinical
Leukemia	Nuclear transport inhibition	Preclinical
Melanoma	AKT/mTOR pathway suppression	Preclinical

Source: MDPI Pharmaceuticals, "Ivermectin as an Alternative Anticancer Agent - A Review," 2025

Fenbendazole: The Veterinary Connection

Fenbendazole, a veterinary antiparasitic chemically similar to Mebendazole, has gained attention in cancer research communities. While not approved for human use, its structural similarity has prompted researchers to investigate whether Mebendazole—the human-approved equivalent—produces comparable effects.

Important Distinction

Fenbendazole is approved for veterinary use only. Mebendazole is the FDA-approved human equivalent with established safety profiles for human consumption. Research findings on Fenbendazole mechanisms are often extrapolated to Mebendazole due to structural similarities, but patients should only use FDA-approved medications prescribed by licensed physicians.

The FLCCC and Clinical Practice

The Front Line COVID-19 Critical Care Alliance (FLCCC) has expanded its focus beyond COVID-19 to include cancer treatment protocols incorporating repurposed drugs. Their approach emphasizes:

Combination therapy: Using multiple repurposed drugs with synergistic mechanisms
Metabolic targeting: Addressing cancer cell energy metabolism
Repurposed drug integration: Combining with standard of care when appropriate

While the FLCCC protocols have generated significant patient interest, medical authorities emphasize that these approaches should be pursued under qualified medical supervision with appropriate clinical monitoring.

The Recommended Protocol via Jase Medical

For patients seeking access to Ivermectin and Mebendazole through licensed medical consultation, our partner Jase Medical provides:

Paper-based physician consultation (no video call required)
US-licensed physicians reviewing applications within 24 hours
Discreet shipping from US-licensed pharmacies
Emergency supply options for travel and preparedness
Protocol guidance for approved antiparasitic indications

This protocol is for approved antiparasitic indications. Cancer applications remain investigational and should only be pursued under oncology specialist supervision.

Access Licensed Physician Consultation

Connect with US-licensed physicians for Ivermectin and Mebendazole prescriptions. Paper-based review process—no video call required. Discreet home delivery.

Start Your Consultation with Jase Medical

Mebendazole Clinical Trials: Current Status

Multiple clinical trials are actively investigating Mebendazole for cancer applications:

Active Clinical Trials (ClinicalTrials.gov)

Glioblastoma Multiforme: Phase I/II trials at Johns Hopkins and other institutions examining Mebendazole as adjunct therapy following standard treatment.

Colon Cancer: Investigational studies combining Mebendazole with chemotherapy agents to overcome resistance.

Pediatric Brain Tumors: Early-phase safety and dosing studies in children with recurrent tumors.

Source: ClinicalTrials.gov database search "Mebendazole oncology"

These trials represent the critical pathway from preclinical research to evidence-based clinical practice. Results from well-designed clinical trials will determine whether repurposed antiparasitics become standard oncology treatments.

Telehealth Access: The Modern Prescription Pathway

For patients seeking Ivermectin and Mebendazole prescriptions, telehealth platforms have streamlined the consultation process. Unlike traditional healthcare requiring:

Weeks-long appointment waits
In-person visits for parasitic concerns
Multiple pharmacy visits

Modern telehealth services like Jase Medical offer:

Online health questionnaires completed in minutes
24-hour physician review by US-licensed doctors
Direct pharmacy fulfillment from US-licensed pharmacies
Discreet packaging delivered to your door
Emergency supply options for travel and preparedness

This approach maintains proper medical oversight while eliminating traditional barriers to accessing these established medications.

Learn more about our full range of telehealth prescription services.

Frequently Asked Questions

Is the Ivermectin/Mebendazole cancer protocol FDA-approved?

No. While Ivermectin and Mebendazole are FDA-approved for antiparasitic indications, their use for cancer treatment remains investigational. The Baghli-Martinez protocol and similar approaches are based on preclinical and early clinical research. Patients interested in these medications for cancer should consult with oncology specialists and consider participation in clinical trials when available.

What did the CIA cancer documents actually reveal?

According to 2025 Daily Mail reporting, the declassified 1951 CIA documents suggest early government researchers observed correlations between parasitic infection treatment and cancer regression in some patients. The documents remained classified for over 60 years. While the observations were preliminary, they suggest early institutional awareness of the parasite-cancer connection that modern research is now investigating systematically.

How can I access Ivermectin and Mebendazole legally?

Both medications require a prescription in the United States. You can access them through traditional healthcare providers or telehealth services like Jase Medical, which offers paper-based physician consultation with 24-hour review. Medications ship discreetly from US-licensed pharmacies to your home. Prescriptions are issued for approved antiparasitic indications.

What's the difference between Mebendazole and Fenbendazole?

Mebendazole is FDA-approved for human use to treat intestinal parasites. Fenbendazole is chemically similar but approved only for veterinary use in animals. While both belong to the benzimidazole class and share mechanisms, patients should only use FDA-approved medications prescribed by licensed physicians. Research on Fenbendazole is often extrapolated to Mebendazole due to structural similarities.

Are there clinical trials I can participate in?

Yes. Active clinical trials investigating Mebendazole for glioblastoma, colon cancer, and pediatric brain tumors are ongoing at institutions including Johns Hopkins. Search ClinicalTrials.gov for "Mebendazole oncology" to find recruiting studies. Participation typically requires meeting specific eligibility criteria and may involve travel to study sites.

What are the side effects of this protocol?

Both medications have established safety profiles for their approved antiparasitic indications. Common side effects include gastrointestinal symptoms (nausea, diarrhea, abdominal pain), headache, and dizziness. Serious side effects are rare. However, using these medications for unapproved indications (including cancer) should only be done under medical supervision, as dosing, duration, and monitoring requirements may differ from standard antiparasitic use.

How quickly does the protocol work for parasites?

For approved antiparasitic indications, both medications typically show effectiveness within 24-72 hours. Many intestinal parasites are eliminated with single-dose treatment. Symptom relief often begins within 1-3 days. For complex infections or specific parasite types, extended dosing may be required as determined by your prescribing physician.

Medical Disclaimer

This article is for informational purposes only and does not constitute medical advice. The Ivermectin/Mebendazole cancer protocol remains investigational and is not FDA-approved for oncology indications. Always consult qualified healthcare providers, including oncology specialists, before starting any new treatment regimen. Never discontinue prescribed cancer treatments without consulting your physician.

Affiliate Disclosure: This article contains affiliate links to Jase Medical. We may earn a commission if you make a purchase through our links at no additional cost to you. Our recommendations are based on thorough research and genuine value to readers. This content is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any medication.

Key Takeaways

The September 2024 Baghli-Martinez protocol represents peer-reviewed research on Ivermectin and Mebendazole targeting cancer stem cells through mitochondrial disruption
CIA declassification of 1951 documents revealed early government awareness of cancer-parasite connections that remained hidden for 60+ years
Drug repurposing offers 90% cost reduction and 3-5x faster development timelines compared to new cancer drugs
Both medications are FDA-approved for antiparasitic use and accessible through licensed telehealth physicians like Jase Medical
Active clinical trials at Johns Hopkins and other institutions are investigating Mebendazole for glioblastoma and other cancers
Cancer applications remain investigational—patients should pursue these approaches only under qualified medical supervision

About GetPrescribed.org

We consider ourselves the yellowpages but for USA Telehealth Services.

We partner with telehealth prescription services and pharmacy fulfillment for patients seeking access to medications at the forefront of medical research. Our platform connects you with US-licensed physicians who can approve your Ivermectin and Mebendazole applications for prescription within 24 hours and ship your protocol to your home discreetly from their online US-licensed pharmacy.

This article is for informational purposes only and does not constitute medical advice. Always consult qualified healthcare providers before starting new treatments.